COVID-19 – Global Health Press

GHP News Latest Science

Needle-free pan-sarbecovirus vaccine clears phase 1 safety milestone, but broad protection remains unproven

Summary This open-label, first-in-human phase 1 dose-escalation trial evaluated the DNA vaccine pEVAC-PS, a computationally designed pan-sarbecovirus candidate delivered intradermally by needle-free PharmaJet Tropis in...

21 July, 2026

2 min read

GHP News Latest Science

Long COVID: An update for clinical practice

Long COVID: an update for your medical practice Long COVID is best conceptualized as one or several post‑infectious syndromes: a disease with a known trigger (SARS‑CoV‑2 infection) that develops in only a definable...

8 July, 2026

8 min read

GHP News Latest Science

The Bundibugyo Outbreak is exposing the world’s preparedness gap — again

The rapidly escalating Bundibugyo Ebola outbreak in the Democratic Republic of the Congo and Uganda is more than a regional health emergency. It is another stress test of whether the world has genuinely learned anything...

4 June, 2026

3 min read

GHP News Latest Science

Literature update ViVa week 19-2026

1. Australia’s child flu vaccine slide is the real post-COVID warning This multicenter prospective test-negative surveillance study enrolled 8,762 influenza-positive hospitalizations and 10,955 influenza-negative...

13 May, 2026

20 min read

GHP News Latest Science

Vaccines and Vaccination (ViVa) 18 news

Over the last week, developments have centered on immunization weeks and campaign intensification, selective adult RSV and influenza policy refinements, and several notable regulatory and manufacturing moves for...

7 May, 2026

10 min read

GHP News Latest Science

Literature update ViVa week 15-2026

1. Long COVID research needs patient peer review – not just patient quotes In a Lancet Infectious Diseases Comment, the authors argue that long COVID research systematically incorporates patient expertise via routine...

14 April, 2026

13 min read

GHP News Infographic

Global vaccine production – Estimated key figures (2025-2026)

Download Infographic Overview Global vaccine production is estimated at approximately 14.5 billion doses annually. The global vaccine market reached around $35 billion in revenue in 2024–2025. Major global players...

9 April, 2026

1 min read

GHP News Latest Science

WHO´s SAGE meeting March 2026: Key updates on COVID-19, Typhoid, and Polio vaccination strategies

Typhoid conjugate vaccine: primary target groups SAGE recommends introducing TCV in countries or settings with high or very high typhoid incidence, or with a substantial burden of antimicrobial-resistant S...

8 April, 2026

4 min read

GHP News Latest Science

Myocarditis and mRNA COVID-19 vaccines 2026: signal, data, and interpretation

In 2021, surveillance systems in multiple countries detected a safety signal for myocarditis and pericarditis after mRNA COVID‑19 vaccination, particularly in adolescent and young adult males. Three years later, the...

25 March, 2026

8 min read

GHP News Latest Science

Global and regional updates on COVID-19 vaccines–associated myocarditis

Global / Multicontinental COVID-19 vaccine myocarditis signal: updated interpretation CIDRAP summarises current evidence that the early myocarditis signal with mRNA COVID-19 vaccines in young males was real but now...

25 March, 2026

2 min read

Tag - COVID-19